Program
intismeran autogene
Also written as “Intismeran autogene”, “mRNA-4157” and “Intismeran”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Renal Cell · Carcinoma, Squamous Cell, led by 2 companies.
Drug pageIntismeran autogene: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 109 open or running | phase 3since Jun 27, 2023 | Jun 27, 2023 | Apr 23, 2027phase 2 · NCT06305767 |
| Moderna | 22 open or running | phase 2since Mar 29, 2019 | Oct 13, 2017 | Nov 21, 2027phase 1 · NCT03313778 |
- Named in Merck’s own pipeline as
intismeran autogene (V940)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentMerck develops it with Moderna, worldwide, costs and profits shared equally.Announced Oct 12, 2022 · Source: Merck, Oct 12, 2022
History and studies of Moderna only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 13, 2017First study: phase 1 study in Solid TumorsFirst studyNCT03313778 · 161 enrolled · United States, Australia, Japan and more
- Mar 29, 2019Phase 2 study in MelanomaNCT03897881 · 267 enrolled · United States, Australia
- Oct 12, 2022Merck develops it with ModernaCo-developmentWorldwide, costs and profits shared equally · announced · Merck
- Aug 11, 2024Named intismeran autogeneINNProposed as its International Nonproprietary Name in WHO's List 131
Ahead
- Nov 21, 2027Primary completion: phase 1 study in Solid TumorsNCT03313778
- Nov 21, 2032Primary completion: phase 2 study in MelanomaNCT03897881
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities.…”NCIt, read by Claude
Studies
All 2 Moderna leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03897881Melanoma · United States, Australia | 2 | Active, not recruiting | Nov 21, 2032 | 267 |
| NCT03313778Solid Tumors · United States, Australia, Japan and more | 1 | Active, not recruiting | Nov 21, 2027 | 161 |
How it is read
Names in the registry
- “Intismeran autogene”, 8 entries
- “mRNA-4157”, 2 entries
- “Intismeran”, 1 entry
- “Intismeran Autogene”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 3 studies
- Non-Muscle Invasive Bladder Neoplasms, 1 study
- Carcinoma, Renal Cell, 1 study
- Carcinoma, Squamous Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.